利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

38 条记录 (耗时 0.025 秒)

    BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES
    2.
    发明公开
    BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES 有权
    国际志愿者联合会（VEBINDUNG UNDERRE VISBINDUNG UND IHRE VERWENDUNGFÜRMEDISINISCHE ZWECKE）

    公开(公告)号：EP2669279A1

    公开(公告)日：2013-12-04

    申请号：EP12738803.1

    申请日：2012-01-26

    申请人： ONO Pharmaceutical Co., Ltd.

    发明人： KAMBE, Tohru ,  SUGIMOTO, Isamu

    IPC分类号： C07D313/06 ,  A61K31/335 ,  A61P27/02 ,  A61P27/06 ,  A61P27/12 ,  A61P43/00 ,  C07D407/04 ,  C07D417/04

    CPC分类号： C07D313/06 ,  C07D313/08 ,  C07D405/06 ,  C07D407/04 ,  C07D407/06 ,  C07D407/12 ,  C07D407/14 ,  C07D417/04 ,  C07F7/1856

    摘要： Provided is a compound which has strong and sustaining intraocular pressure lowering action and, further, has no fear of side effect on eyes.
    Since a compound represented by the formula (I):

    wherein definition of each group is as described in the specification, or a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering action and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc.

    摘要翻译： 本发明提供具有强而持续的眼内压降作用的化合物，而且不会对眼睛产生副作用。 由于由式（I）表示的化合物：其中每个基团的定义如说明书中所述，或其盐，其溶剂合物或其前药具有强烈和持续的眼内压降作用，并且还具有 对眼睛的副作用如眼刺激性（充血，角膜混浊等），房水蛋白上升等，具有高度的安全性，可作为预防和/或治疗青光眼等的优异剂。

    PENTACYCLIC OXEPINES AND DERIVATIVES THEREOF, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
    10.
    发明公开
    PENTACYCLIC OXEPINES AND DERIVATIVES THEREOF, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM 有权
    五环oxepins及其衍生物，PROCESS FOR THEIR和药物组合物含

    公开(公告)号：EP1551822A2

    公开(公告)日：2005-07-13

    申请号：EP03765456.3

    申请日：2003-07-18

    申请人： ELI LILLY AND COMPANY

    发明人： HINKLIN, Ronald, Jay ,  WALLACE, Owen, Brendan

    IPC分类号： C07D313/00

    CPC分类号： C07D409/10 ,  C07D313/06 ,  C07D313/10 ,  C07D333/56 ,  C07D495/04

    摘要： The present invention provides a compound of the formula (I) wherein R1 is -H, -OH, -O(C1-C4 alkyl), -OCOC6H5, -OCO(C1-C6 alkyl), or -OSO2(C2-C6 alkyl); R0, R2 and R3 are each independently -H, -OH, -O(C1-C4 alkyl), -OCOC6H5, -OCO(C1-C6 alkyl), -OSO2(C2-C6 alkyl) or halo; R4 is 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino, diisopropylamino, or 1-hexamethyleneimino; n is 2 or 3 X is -S- or -HC=CH-; G is -O-, -S-, -SO-, SO2, or -N(R5)-, wherein R5 is -H or C1-C4 alkyl; and Y is -O-, -S-, -NH-, -NMe-, or -CH2-; or a pharmaceutically acceptable salt thereof; pharmaceutical compositions thereof, optionally in combination with estrogen and progestin; methods of inhibiting a disease associated with estrogen deprivation; and methods for inhibiting a disease associated with an aberrant physiological response to endogenous estrogen.